Innovative model highlights bone marrow transplantation without toxic side effects.

Study is the first to validate allostatic load as measurable in teens.

New model and vector may hold the keys to transforming the lives of XLSA patients.

Children’s Hospital of Philadelphia (CHOP) today announced that it has received a significant philanthropic gift from Mitchell L. Morgan, Dr. Hilarie L. Morgan and their family to name its state-of-the-art research facility currently under construction on the South Street bridge next to CHOP’s Roberts Center for Pediatric Research.

The findings from the clinical trial were published in the New England Journal of Medicine.

Researchers at Children’s Hospital of Philadelphia (CHOP) and the Perelman School of Medicine at the University of Pennsylvania revealed a powerful new bone marrow atlas that will offer the public a first-of-its-kind visual passport into the spectrum of healthy and diseased blood production.

Target gene could serve as the basis of a future therapeutic intervention.

The study identified obstacles like limited time during clinical visits, a lack of comprehensive resources, and insufficient notice from caregivers to prepare for discussions.

In a landmark study, an international consortium led by researchers at CHOP published the final results of a key clinical trial of the gene therapy CASGEVY for the treatment of sickle cell disease.

Findings provide some of the first evidence of potential therapeutic targets for condition affecting thousands of patients with single ventricle congenital heart disease.